Mission
We were founded on a mission to pursue the impossible. Our mission is to develop non-toxic, first-in-class/best-in-class, curative therapies for patients with devastating diseases. This is at the heart of all that we do. ClearCure Biosciences, Inc. is a clinical-stage biopharmaceutical company, dedicated to moving the world from sick care to health care.
Vision
Our vision is preventing, reversing and curing diseases. We are scaling up and pursuing a multi-program/multi-technology drug discovery pipeline. Our business model is internal research, collaborations, partnering, and acquisitions for faster cures.
Values
Our company values are trust, curiosity, and optimism. Guided by sound scientific data, we are relentlessly building on our small molecule oncological drug development expertise and platform technologies in the pursuit of transformative medicines; for very hard to treat advanced cancers, sepsis, and Alzheimer’s as first to market. Our innovations stem from out-of-the-box thinking, ingenuity, and boldness. However, we approach these unmet medical needs with purpose, dedication, and humbleness.
Leadership
Innovative drug designer and developer with years of experience in designing novel and complex pharmaceutical structures from natural products’ chemistry. Expertise in developing new pharmaceuticals, medical devices, and consumer health and wellness products. Inventor of well-over 1000 novel drug structures for cancer and other disease states. Designed and patented the world’s first water beverage clinically formulated and proven to reverse DNA damage and oxidative cellular stress from air pollution, traffic pollution, several known serious food carcinogens. She recently was granted a new patent for a 100 novel breast cancer drugs. She holds 4 issued patents for pharma and medical devices. Many newer pharmaceutical drug candidates are pending.
Double Board Certified in Otolaryngology and Plastic Surgery, Dr. Rose has been a medical school Associate Professor of Microbiology and Surgery for the past 2 decades. He is extensively published in both clinical and bench research and has authored two books.
Rheumatologist and clinical immunologist with proven skills in pharmaceutical study design. Previous Vice President of Medical, Science, Inflammation at NovoNordisk . Oversaw early development program of monoclonal antibodies for inflammatory diseases, including inflammatory bowel disease, systemic lupus, rheumatoid arthritis and psoriasis. Bristol Myers Squibb- where he directed clinical development of abatacept programs in juvenile idiopathic arthritis, psoriatic arthritis and lupus (separate programs in systemic and renal lupus). Defended juvenile idiopathic arthritis results at EMEA approval hearings Directed exploratory study of dasatinib.
